Phase 3 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study.
• People aged 18 or older at the time of signing the consent form.
• People with a confirmed diagnosis of multiple myeloma, diagnosed using standard international criteria.
• People whose myeloma can be measured through blood or urine tests at the start of the study (specific protein or light chain levels must meet defined thresholds — confirm with trial site).
• People whose myeloma showed at least a partial response to at least one previous treatment.
• People whose myeloma has come back and stopped responding to treatment, and who have previously been treated with two specific types of myeloma therapy known as proteasome inhibitors and immunomodulatory drugs.
• People with a general health and activity level rated as reasonably functional (scored 0–2 on a standard medical scale — confirm with trial site).
• People who are not pregnant and who are willing to use contraception during the study.
• People who agree to have a bone marrow biopsy as part of the study.

Who may not be able to join:

• People who have previously been treated with daratumumab or any other therapy that targets a protein called CD38.
• People who received myeloma treatment within 2 weeks (or within 5 half-lives of the drug) before joining the study, except for a short course of steroid medication.
• People who had a stem cell transplant using their own cells within 12 weeks before joining the study.
• People who have ever had a stem cell transplant using donor cells, regardless of when it occurred.
• People who have a stem cell transplant planned before their disease progresses during this study.
• People diagnosed with plasma cell leukemia, POEMS syndrome, or amyloidosis.
• People with a condition called Waldenström macroglobulinemia or similar conditions involving high levels of a certain protein, where there is no evidence of the specific bone-affecting cell growth seen in multiple myeloma.
• People who have had another cancer in the past 5 years, except for certain early-stage or non-invasive skin or cervical cancers that have been fully treated and are considered low risk for returning (confirm with trial site).
• People who have undergone a plasma-filtering procedure called plasmapheresis within 28 days before joining the study.
• People who show signs that their myeloma has spread to the membranes surrounding the brain or spinal cord.
• People who are pregnant or breastfeeding, or who are planning a pregnancy during the study or within 3 months after the last dose of the study drug. This also applies to male participants who are planning to father a child during the study or within 3 months after the last dose.

Important: Always verify eligibility with the trial site directly before applying.